Biota Pharmaceuticals Inc., of Atlanta, said the Department of Health and Human Services and the Biomedical Advanced Research and Development Authority (BARDA) provided an interim update regarding the recent stop-work order from BARDA and its pending decision on an in-process review (IPR) of the contract supporting the development of laninamivir octanoate.